{"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"pygments_lexer":"ipython3","nbconvert_exporter":"python","version":"3.6.4","file_extension":".py","codemirror_mode":{"name":"ipython","version":3},"name":"python","mimetype":"text/x-python"}},"nbformat_minor":4,"nbformat":4,"cells":[{"cell_type":"markdown","source":"**Recent advancements in AI health care**\n\nAlphaFold:\nAlphaFold is a protein structure prediction algorithm developed by DeepMind, a subsidiary of Google AI. It was first announced in November 2020, and it has since revolutionized the field of structural biology.\nProteins are the building blocks of life, and they play a critical role in many biological processes. However, the structure of proteins is often difficult to determine, which has limited our understanding of how they work. AlphaFold is able to predict the structure of proteins with unprecedented accuracy, which has opened up new possibilities for research in biology, medicine, and drug discovery.\nAlphaFold works by using a combination of deep learning and physical principles. It first uses deep learning to generate a large number of possible protein structures. These structures are then evaluated using physical principles, such as the laws of thermodynamics and molecular dynamics. The structure with the lowest energy is then selected as the most likely structure.\nAlphaFold has been shown to be highly accurate in predicting the structure of proteins. In the CASP14 competition, which is a benchmark for protein structure prediction, AlphaFold achieved a top score of 92.4% accuracy. This is significantly higher than the previous state-of-the-art, which was only 72.2% accuracy.\nThe accuracy of AlphaFold has had a major impact on the field of structural biology. It has allowed scientists to better understand the structure and function of proteins, which has led to new insights into many biological processes. For example, AlphaFold has been used to help identify new drug targets for diseases such as Alzheimer's and cancer.\nAlphaFold is still under development, but it has the potential to revolutionize the field of biology. It could lead to new treatments for diseases, new insights into how the body works, and even new forms of life.\nHere are some of the benefits of AlphaFold:\nIt can predict the structure of proteins with unprecedented accuracy.\nIt can help scientists to better understand the structure and function of proteins.\nIt can lead to new treatments for diseases.\nIt can lead to new insights into how the body works.\nIt can even lead to new forms of life.\nHere are some of the challenges of AlphaFold:\nIt is still under development, and it is not yet perfect.\nIt is computationally expensive to run.\nIt is not yet clear how AlphaFold can be used to predict the structure of proteins in complex environments, such as inside cells.\nOverall, AlphaFold is a powerful tool that has the potential to revolutionize the field of biology. It is still under development, but it has already had a major impact on the field. As AlphaFold continues to develop, it is likely to lead to even more breakthroughs in the years to come.\n\nAuris Health is a medical technology company that develops and markets robotically-assisted bronchoscopes. The company's flagship product is the Monarch Platform, which is designed to help physicians diagnose and treat lung cancer.\nAuris Health was founded in 2007 by Frederic Moll, who is also the co-founder of Hansen Medical, another medical technology company. The company is headquartered in Mountain View, California, and it has raised over $1 billion in funding.\nThe Monarch Platform is a flexible robotic bronchoscope that is designed to navigate through the airways of the lung. The platform is equipped with a variety of tools, including a camera, a biopsy needle, and a laser. These tools allow physicians to visualize the airways, take biopsies, and perform minimally invasive procedures.\nThe Monarch Platform is currently approved by the FDA for use in diagnostic bronchoscopy. The company is also conducting clinical trials to evaluate the platform for use in therapeutic bronchoscopy.\nAuris Health is a privately held company, and it is not yet profitable. However, the company has a strong pipeline of products in development, and it is expected to grow significantly in the coming years.\nHere are some of the benefits of Auris Health's technology:\nIt can help physicians to diagnose and treat lung cancer more accurately and efficiently.\nIt can reduce the risk of complications associated with traditional bronchoscopy.\nIt can improve the quality of life for patients with lung cancer.\nHere are some of the challenges facing Auris Health:\nThe company is still in the early stages of commercialization, and it is not yet profitable.\nThe company faces competition from other companies that are developing robotic bronchoscopes.\nThe company needs to demonstrate the safety and effectiveness of its technology in larger clinical trials.\nOverall, Auris Health is a promising medical technology company with the potential to revolutionize the treatment of lung cancer. The company's technology has the potential to improve the accuracy and efficiency of diagnosis and treatment, and it could also reduce the risk of complications. However, the company is still in the early stages of commercialization, and it faces some challenges.\nAtomwise:\n\nAtomwise is a San Francisco-based company that uses artificial intelligence (AI) to discover new drugs. The company's platform, AtomNet, uses deep learning to analyze large datasets of chemical compounds and identify those with potential therapeutic properties.\nAtomwise was founded in 2012 by Izhar Wallach and Dror Sharon. The company has raised over $200 million in funding, and it has partnerships with several pharmaceutical companies, including Novartis, AstraZeneca, and Pfizer.\nAtomNet has been used to discover several potential drug candidates for a variety of diseases, including cancer, Alzheimer's disease, and HIV. In 2019, Atomwise entered into a partnership with the Bill & Melinda Gates Foundation to use AtomNet to discover new drugs for neglected tropical diseases.\nAtomwise is a privately held company, and it is not yet profitable. However, the company has a strong pipeline of drug candidates in development, and it is expected to grow significantly in the coming years.\nHere are some of the benefits of Atomwise's technology:\nIt can help to discover new drugs more quickly and efficiently than traditional methods.\nIt can identify drug candidates that would not have been discovered by traditional methods.\nIt can reduce the cost of drug discovery.\nHere are some of the challenges facing Atomwise:\nThe company is still in the early stages of development, and it has not yet brought any drugs to market.\nThe company faces competition from other AI-powered drug discovery companies.\nThe company needs to demonstrate the safety and efficacy of its drug candidates in clinical trials.\nOverall, Atomwise is a promising company with the potential to revolutionize the drug discovery process. The company's AI-powered platform has the potential to discover new drugs more quickly and efficiently than traditional methods, and it could reduce the cost of drug discovery. However, the company is still in the early stages of development, and it faces some challenges.\n\n","metadata":{}},{"cell_type":"code","source":"import pandas as pd\n\n# Create a sample DataFrame\ndata = {'type':['essay_category','essay_url','feedback1_url','feedback2_url','feedback3_url'],\n    'value': ['AIin healthcare','https://www.kaggle.com/laalinibhgoadi/recent-advancements-in-field-of-ai-in-healthcare','https://www.kaggle.com/code/kobbiemanrique/2023-kaggle-ai-report-tabular-data/comments#2329607','https://www.kaggle.com/code/lalexanderw/the-open-question-tabular-processing/comments#2329612','https://www.kaggle.com/code/pawanthapaliya/tabular-and-time-series-data/comments#2329617']\n}\n\ndf = pd.DataFrame(data)\n\n# Write DataFrame to a CSV file\ndf.to_csv('submissions.csv', index=False)\n","metadata":{"execution":{"iopub.status.busy":"2023-07-06T00:15:48.908555Z","iopub.execute_input":"2023-07-06T00:15:48.909002Z","iopub.status.idle":"2023-07-06T00:15:48.952179Z","shell.execute_reply.started":"2023-07-06T00:15:48.908969Z","shell.execute_reply":"2023-07-06T00:15:48.951179Z"},"trusted":true},"execution_count":null,"outputs":[]}]}